Nanoencapsulation of olanzapine increases its efficacy in antipsychotic treatment and reduces adverse effects

Journal of Biomedical Nanotechnology

Volumn 10, Issue 6, 2014, Pages 1137-1145

  Dimer, Frantiescoli A ^a   Ortiz, Manoel ^a   Pase, Camila S ^b   Roversi, Katiane ^b   Friedrich, Rossana B ^a   Pohlmann, Adriana R ^a   Burger, Marilise E ^b   Guterres, Silvia S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

Adverse effects; Antipsychotic activity; Lipid Core nanocapsules; Olanzapine; Rats; Weight gain

Indexed keywords

ENCAPSULATION; NANOCAPSULES; PATIENT TREATMENT; RATING; ZETA POTENTIAL;

ADVERSE EFFECT; ANTIPSYCHOTIC ACTIVITIES; LIPID-CORE NANOCAPSULES; OLANZAPINE; WEIGHT GAIN;

DRUG PRODUCTS;

AMPHETAMINE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NANOCAPSULE; OLANZAPINE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISPERSION; DRUG EFFICACY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; LASER DIFFRACTION; MALE; NANOENCAPSULATION; NONHUMAN; PH; PHYSICAL CHEMISTRY; RAT; STEREOTYPY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; ZETA POTENTIAL;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIFFUSION; DRUG SYNERGISM; MALE; MENTAL DISORDERS; NANOCAPSULES; PARTICLE SIZE; PSYCHOTIC DISORDERS; RATS; RATS, WISTAR; SURFACE PROPERTIES; TREATMENT OUTCOME;

EID: 84898413479     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1817     Document Type: Article

References (55)

1. S. Kapur and G. Remington, Atypical antipsychotics: New directions and new challenges in the treatment of schizophrenia. Annu. Rev. Med. 52, 503 (2001).
2. M. Olfson, D. Mechanic, S. Hansell, C. A. Boyer, J. Walkup, and P. J. Weiden, Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr. Serv. 51, 216 (2000).
3. A. H. Rubenstein, Obesity: A modern epidemic. Trans. Am. Clin. Climatol. Assoc. 116, 103 (2005).
4. T. Suzuki, G. Remington, B. H. Mulsant, H. Uchida, T. K. Rajji, A. Graff-Guerrero, M. Mimura, and D. C. Mamo, Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. Psychiatry Res. 197, 1 (2012).
5. S. Choi, B. DiSilvio, J. Unangst, and J. D. Fernstrom, Effect of chronic infusion of olanzapine and clozapine on food intake and body weight gain in male and female rats. Life Sci. 81, 1024 (2007).
6. D. B. Allison, J. L. Mentore, M. Heo, L. P. Chandler, J. C. Cappelleri, M. C. Infante, and P. J. Weiden, Antipsychotic-induced weight gain: A comprehensive research synthesis. A. J. Psychiatry 156, 1686 (1999).
7. M. J. Fell, R. Gibson, E. McDermott, G. Sisodia, K. M. Marshall, and J. C. Neill, Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behav. Brain Res. 160, 338 (2005).
8. J. Minet-Ringuet, P. Even, M. Lacroix, D. Tomé, and R. de Beaurepaire, A model for antipsychotic-induced obesity in the male rat. Psychopharmacology 187, 447 (2006).
9. R. K. McNamara, R. Jandacek, T. Rider, P. Tso, A. Cole-Strauss, and J. W. Lipton, Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: Relationship with stearoyl-CoA desaturase activity. Schizophr. Res. 129, 66 (2011).
10. M.-B. Assié, E. Carilla-Durand, L. Bardin, M. Maraval, M. Aliaga, N. Malfètes, M. Barbara, and A. Newman-Tancredi, The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: Comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur. J. Pharmacol. 592, 160 (2008).
11. J. Minet-Ringuet, P. C. Even, M. Goubern, D. Tomé, and R. D. Beaurepaire, Long term treatment with olanzapine mixed with the food in male rats induces body fat deposition with no increase in body weight and no thermogenic alteration. Appetite 46, 254 (2006).
12. V. L. Albaugh, J. G. Judson, P. She, C. H. Lang, K. P. Maresca, J. L. Joyal, and C. J. Lynch, Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol. Psychiatry 16, 569 (2011).
13. H. S. Vestri, L. Maianu, D. R. Moellering, and W. T. Garvey, Atypical antipsychotic drugs directly impair insulin action in adipocytes: Effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32, 765 (2006).
14. K. Linnet and T. B. Ejsing, A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur. Neuropsychopharmacol. 18, 157 (2008).
15. R. L. Frozza, A. Bernardi, K. Paese, J. B. Hoppe, T. da Silva, A. M. Battastini, A. R. Pohlmann, S. S. Guterres, and C. Salbego, Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J. Biomed. Nanotech. 6, 694 (2010).
16. F. Figueiró, A. Bernardi, R. L. Frozza, T. Terroso, A. Zanotto-Filho, E. H. F. Jandrey, J. Moreira, F. Claudio, C. G. Salbego, M. I. Edelweiss, A. R. Pohlmann, S. Guterres, S. Lvia, and A. M. O. Battastini, Resveratrol-loaded lipid-core nanocapsules treatment reduces in vitro and in vivo glioma growth. J. Biomed. Nanotech. 9, 516 (2013).
17. M. C. Fontana, K. Coradini, S. S. Guterres, A. R. Pohlmann, and R. C. R. Beck, Nanoencapsulation as a way to control the release and to increase the photostability of clobetasol propionate: Influence of the nanostructured system. J. Biomed. Nanotech. 5, 254 (2009).
18. K. Jörg, Nanoparticles - A historical perspective. Int. J. Pharm. 331, 1 (2007).
19. C. E. Mora-Huertas, H. Fessi and A. Elaissari, Polymer-based nanocapsules for drug delivery. Int. J. Pharm. 385, 113 (2010).
20. A. Bernardi, E. Braganhol, E. Jäger, F. Figueiró, M. I. Edelweiss, A. R. Pohlmann, S. S. Guterres, and A. M. O. Battastini, Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model. Cancer Lett. 281, 53 (2009).
21. E. Jäger, C. G. Venturini, F. S. Poletto, L. M. Colomé, J. P. U. Pohlmann, A. Bernardi, A. M. O. Battastini, S. S. Guterres, and A. R. Pohlmann, Sustained release from lipid-core nanocapsules by varying the core viscosity and the particle surface area. J. Biomed. Nanotech. 5, 130 (2009).
22. W. T. Carpenter and J. I. Koenig, The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology 33, 2061 (2007).
23. P. A. Arguello and J. A. Gogos, Modeling madness in mice: One piece at a time. Neuron 52, 179 (2006).
24. D. M. Benvegnu, R. C. S. Barcelos, N. Boufleur, P. Reckziegel, C. S. Pase, A. F. Ourique, R. C. R. Beck, and M. E. Bürger, Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. Eur. J. Pharm. Biopharm. 77, 332 (2011).
25. T. Futamura, S. Akiyama, H. Sugino, A. Forbes, R. D. McQuade, and T. Kikuchi, Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Prog. Neuropsychopharmacol. Bol. Psychiatry 34, 1115 (2010).
26. K. Yui, S. Ikemoto, T. Ishiguro, and K. Goto, Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia. Ann. N. Y. Acad. Sci. 914, 1 (2000).
27. F. A. Dimer, A. R. Pohlmann, and S. S. Guterres, Characterization of rheology and release profiles of olanzapine-loaded lipid-core nanocapsules in thermosensitive hydrogel. J. Nanosci. Nanotechnol. 13, 8144 (2013).
28. D. S. Jornada, L. A. Fiel, K. Bueno, J. F. Gerent, C. L. Petzhold, R. C. R. Beck, S. S. Guterres, and A. R. Pohlmann, Lipid-core nanocapsules: Mechanism of self-assembly, control of size and loading Delivered by Publishing Technology IP: 203.56.241.128 On: Thu,Copyright: American capacity. Soft Matter 8, 6646 (2012).
29. Council for International Organization of Medical Sciences, The International Council for Laboratory Animal Science, International Guiding Principles for Biomedical Research Involving Animals (2012).
30. F. J. Sanchez-Muniz and S. Bastida, Do not use the Friedewald formula to calculate LDL-cholesterol in hypercholesterolaemic rats. Eur. J. Lipid Sci. Technol. 110, 295 (2008).
31. H. Ujike, K. Akiyama, and S. Otsuki, D-2 but not D-1 dopamine agonists produce augmented behavioral response in rats after subchronic treatment with methamphetamine or cocaine. Psychopharmacology (Berl.) 102, 459 (1990).
32. M. E. Bardgett, W. M. Humphrey, and J. G. Csernansky, The effects of excitotoxic hippocampal lesions in rats on risperidone- and olanzapine-induced locomotor suppression. Neuropsychopharmacology 27, 930 (2002).
33. M. Kalinichev, C. Rourke, A. Daniels, M. Grizzle, C. Britt, D. Ignar, and D. Jones, Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology 182, 220 (2005).
34. R. Coccurello, A. Caprioli, O. Ghirardi, R. Conti, B. Ciani, S. Daniele, A. Bartolomucci, and A. Moles, Chronic administration of olanzapine induces metabolic and food intake alterations: A mouse model of the atypical antipsychotic-associated adverse effects. Psychopharmacology 186, 561 (2006).
35. O. Harush-Frenkel, M. Bivas-Benita, T. Nassar, C. Springer, Y. Sherman, A. Avital, Y. Altschuler, J. Borlak, and S. Benita, A safety and tolerability study of differently-charged nanoparticles for local pulmonary drug delivery. Toxicol. Appl. Pharmacol. 246, 83 (2010).
36. R. P. Bulcao, F. A. Freitas, C. G. Venturini, E. Dallegrave, J. Durgante, G. Goethel, C. T. Cerski, P. Zielinsky, A. R. Pohlmann, S. S. Guterres, and S. C. Garcia, Acute and subchronic toxicity evaluation of poly(epsilon- caprolactone) lipid-core nanocapsules in rats. Toxicol. Sci. 132, 162 (2013).
37. A. I. Zugno, M. Barcelos, L. D. Oliveira, L. Canever, R. D. D. Luca, D. B. Fraga, M. P. Matos, G. T. Rezin, G. Scaini, M. Búrigo, E. L. Streck, and J. Quevedo, Energy metabolism, leptin, and biochemical parameters are altered in rats subjected to the chronic administration of olanzapine. Rev. Bras. Psiq. 34, 168 (2012).
38. K. Weston-Green, X.-F. Huang, and C. Deng, Olanzapine treatment and metabolic dysfunction: A dose response study in female Sprague Dawley rats. Behav. Brain Res. 217, 337 (2011).
39. H. N. Boyda, R. M. Procyshyn, L. Tse, D. Wong, C. C. Pang, W. G. Honer, and A. M. Barr, Intermittent treatment with olanzapine causes sensitization of the metabolic side-effects in rats. Neuropharmacol. 62, 1391 (2012).
40. M. P. St-Onge, A. Bosarge, L. L. Goree, and B. Darnell, Medium chain triglyceride oil consumption as part of a weight loss diet does not lead to an adverse metabolic profile when compared to olive oil. J. Am. Coll. Nutr. 27, 547 (2008).
41. M.-P. St-Onge and P. J. H. Jones, Physiological effects of medium-chain triglycerides: Potential agents in the prevention of obesity. J. Nutr. 132, 329 (2002).
42. J. B. Lasekan, J. Rivera, M. D. Hirvonen, R. E. Keesey, and D. M. Ney, Energy expenditure in rats maintained with intravenous or intragastric infusion of total parenteral nutrition solutions containing medium- or long-chain triglyceride emulsions. J. Nutr. 122, 1483 (1992).
43. V. Van Wymelbeke, A. Himaya, J. Louis-Sylvestre, and M. Fantino, Influence of medium-chain and long-chain triacylglycerols on the control of food intake in men. Am. J. Clin. Nutrit. 68, 226 (1998).
44. N. Baba, E. F. Bracco, and S. A. Hashim, Enhanced thermogenesis and diminished deposition of fat in response to overfeeding with diet containing medium chain triglyceride. Am. J. Clin. Nutrit. 35, 678 (1982).
45. S. T. Henderson, Use of Medium Chain Triglycerides for the Treatment and Prevention of Alzheimer's Disease and Other Diseases Resulting from Reduced Neuronal Metabolism II, Accera, Inc., United States (2004),
46. M. Aravagiri, Y. Teper, and S. R. Marder, Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm. Drug Dispos. 20, 369 (1999).
47. M. S. Muthu, M. K. Rawat, A. Mishra, and S. Singh, PLGA nanoparticle formulations of risperidone: Preparation and neuropharmacological evaluation. Nanomedicine: NBM 5, 323 (2009).
48. J. Kreuter, Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev. 64, 213 (2012).
49. G. Borchard, K. L. Audus, F. Shi, and J. Kreuter, Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int. J. Pharm. 110, 29 (1994).
50. M. Fazil, S. Md, S. Haque, M. Kumar, S. Baboota, J. K. Sahni, and J. Ali, Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur. J. Pharm. Sci. 47, 6 (2012).
51. J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov, Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674, 171 (1995).
52. B. Wilson, M. K. Samanta, K. Santhi, K. P. S. Kumar, N. Paramakrishnan, and B. Suresh, Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 70, 75 (2008).
53. M. Nerurkar, P. Burton, and R. Borchardt, The use of surfactants to enhance the permeability of peptides through caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13, 528 (1996).
54. S. Wohlfart, S. Gelperina, and J. Kreuter, Transport of drugs across the blood-brain barrier by nanoparticles. J. Control Release 161, 264 (2012).
55. B. Dehouck, L. Fenart, M. P. Dehouck, A. Pierce, G. Torpier, and R. Cecchelli, A new function for the LDL receptor: Transcytosis of LDL across the blood-brain barrier. J. Cell Biol. 138, 877 (1997).